Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present a case of AML with an IDH2 mutation treated with a regimen of enasidenib and 5-azacitidine, where thyroiditis was noted to be a part of differentiatio...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-05-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/507613 |